Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Aug 8, 2024
Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024
Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-stage Choroidal Melanoma to be Presented at Retina Society Annual Meeting
Read more at globenewswire.com
